Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 7/20 | 0.56 |
| ▸ | MC5R | P33032 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | MC1R | Q01726 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703677 | 0.91 | MC4R (0.55) | MC4RMC5RMC3RMC1RPOLB | |
| SCHEMBL6047887 | 0.89 | POLB (0.53) | MC4RMC5RMC3RMC1RPOLB | |
| SCHEMBL6047817 | 0.87 | POLB (0.52) | MC4RMC5RMC3RMC1RPOLB | |
| SCHEMBL6047818 | 0.87 | MC4R (0.48) | MC4RMC5RMC3RMC1R | |
| SCHEMBL6047848 | 0.85 | MC4R (0.47) | MC4RMC5RMC3RMC1RMEN1 | |
| SCHEMBL6047758 | 0.85 | POLB (0.57) | MC4RMC5RMC3RMC1RPOLB | |
| SCHEMBL4697852 | 0.84 | LMNA (0.50) | MC4RMC5RMC3RMC1RPOLB | |
| SCHEMBL6047807 | 0.84 | MC4R (0.49) | MC4RMC5RMC3RMC1RPOLB | |
| SCHEMBL4697988 | 0.83 | MC4R (0.46) | MC4RMC5RMC3RMC1RCNR2 | |
| SCHEMBL6047820 | 0.81 | MC4R (0.46) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646614-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| EP-1646614-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | MC4R 1970/4885MC5R 666/4885MC3R 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.